Back

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: SGLT2 inhibitors in heart failure: prevention and treatment Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Vlad Damian Vintila

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

3 More presentations in this session

Presentation thumbnail
Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.
Doctor L. Spadafora (Latina, IT)
Abstract Slides Video
Presentation thumbnail
THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.
Doctor S. Das (Boston, US)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2i treatment at the beginning of real time exposure in a HFrEF population
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources